ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MSMB Capital has proposed acquiring AMAG Pharmaceuticals for $18.00 per share, or $378 million. The New York City-based investment firm says it wants to stop a previously announced merger between AMAG and Allos Therapeutics (C&EN, July 25, page 17). In a letter to AMAG’s board, MSMB’s chief investment officer, Martin Shkreli, notes that AMAG’s stock has dropped since announcement of the deal, which offers its shareholders no premium. Other market watchers have commented on the disparity of the two firms. AMAG markets a semisynthetic coated iron oxide particle for anemia, whereas Allos sells a treatment for a form of lymphoma.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X